ライフサイエンスコーパス: deoxycholate

1 type detergents (i.e., Chapso, glycocholate, deoxycholate).

2 somal amphotericin B; n = 155 amphotericin B deoxycholate).

3 ental strain when treated with the detergent deoxycholate.

4 protein complex because it was abolished by deoxycholate.

5 mily member YegM and pump out novobiocin and deoxycholate.

6 pecific antibodies after solubilization with deoxycholate.

7 wth of C. jejuni cultured in the presence of deoxycholate.

8 rsion of graphene oxide/few-layered graphene/deoxycholate.

9 ge when cells without ygiS are stressed with deoxycholate.

10 t sensitivity to bile salts, specifically to deoxycholate.

11 d tolerance during stress from the bile salt deoxycholate.

12 lymyxin B but did not display sensitivity to deoxycholate.

13 th in the presence of large sugars or sodium deoxycholate.

14 hysiologic levels of the secondary bile acid deoxycholate.

15 g with 0.4% dioleoylphosphatidylcholine/0.4% deoxycholate.

16 gent but lacking dioleoylphosphatidylcholine/deoxycholate.

17 and plate cultures supplemented with sodium deoxycholate.

18 8011 were screened for sensitivity to sodium deoxycholate.

19 ded treatment, which includes amphotericin B deoxycholate (1 mg per kilogram per day) plus flucytosin

20 Treatment with AmB deoxycholate (1 mg/kg/day) or liposomal AmB (5 mg/kg/day

21 ton X-100 (0.3%) or the mild ionic detergent deoxycholate (20 mM); however, higher concentrations of

22 ncreased plasma levels of glycodeoxycholate, deoxycholate 3-sulfate, and bilirubin.

23 amphotericin B (28.2%) versus amphotericin B deoxycholate (34.6%) but was not statistically different

24 4 patients (71%) treated with amphotericin B deoxycholate, 4/12 (33%) treated with a triazole alone,

25 nthetically link 2 of the following ligands: deoxycholate, 5-leuenkephalin, triiodothyronine, thyroni

26 yes treated with L-AmB (75%), amphotericin B deoxycholate (78%), and ABLC (91%) than with the control

27 B host strain to novobiocin (16-fold) and to deoxycholate (8-fold).

28 greater in eyes treated with amphotericin B deoxycholate (81%), L-AmB (91%), and ABLC (97%) than wit

29 man diarrheal illness worldwide, responds to deoxycholate, a component of bile, by altering global ge

30 ound that growth of C. jejuni in medium with deoxycholate, a component of bile, caused DNA damage con

31 effects, zebrafish were treated with sodium deoxycholate, a known inducer of NF-kappaB or NF-kappaB

32 nsitivity to and biofilm induction by sodium deoxycholate, a major bile component that acts as an ext

33 Deoxycholate, a metabolite of cholate produced by the no

34 cholelithogenesis by augmenting formation of deoxycholate, a pro-lithogenic secondary bile salt, and

35 us 10, 20, 30, and 50 micro g amphotericin B deoxycholate, ABLC, and L-AmB.

36 at a high protein concentration; (2) sodium deoxycholate added during the reduction step to minimize

37 isolates grown on blood agar, xylose lysine deoxycholate agar (XLD), Hektoen enteric agar (HE), salm

38 d persistent infection, despite therapy with deoxycholate AmB or liposomal AmB.

39 effect of the combination of amphotericin B deoxycholate (AmB) and 5-fluorocytosine (5FC) by use of

40 erosolized administrations of amphotericin B deoxycholate (AmBd) and amphotericin B lipid complex (AB

41 late 1950s, intrathecal (IT) amphotericin B deoxycholate (AmBd) has been successfully used to treat

42 single high dose of liposomal amphotericin B deoxycholate (AmBisome group) was non-inferior to the WH

43 to receive either intravenous amphotericin B deoxycholate (amphotericin) (219 patients), at a dose of

44 sin digestion in the presence of 0.5% sodium deoxycholate and 10 mM dithiothreitol (DTT).

45 arly, in OE19 human esophageal cancer cells, deoxycholate and acid induced expression of GC-C.

46 encies in minimal medium, in the presence of deoxycholate and bile, and in competition assays with wi

47 ng less active than unconjugated bile salts (deoxycholate and cholate).

48 sistance specifically to the bile components deoxycholate and conjugated forms of chenodeoxycholate,

49 y and mortality between daily amphotericin B deoxycholate and daily liposomal amphotericin B among pe

50 mutant was more sensitive to the detergents deoxycholate and dodecyl sulfate and the antimicrobial p

51 mbination antifungal therapy (amphotericin B deoxycholate and flucytosine) is the recommended treatme

52 increased 7-8-fold with bile duct ligation; deoxycholate and hyodeoxycholate disappeared.

53 AmB deoxycholate and liposomal AmB had the greatest antifung

54 chenodeoxycholate, the secondary bile acids deoxycholate and lithocholate, and 3alpha,7alpha,12alpha

55 evealed elevated levels of homogentisate and deoxycholate and reduced levels of lactate and alanine i

56 d mutants exhibited increased sensitivity to deoxycholate and showed increased resistance to polymyxi

57 he bile salts sodium taurocholate and sodium deoxycholate and significantly increased sensitivity to

58 of toxic compounds, including the bile salt deoxycholate and the hydrophobic dye crystal violet.

59 nt was assayed for its sensitivity to sodium deoxycholate and to the antimicrobial cationic peptide,

60 mutant demonstrated enhanced sensitivity to deoxycholate and was impaired in DNA double strand break

61 IpaD specifically binds fluorescein-labeled deoxycholate and, based on energy transfer measurements

62 d-state and gas-phase structures of cyclotri(deoxycholate) and cyclotetra(24-norcholate).

63 buffer which contains 1% Nonidet P-40, 0.5% deoxycholate, and 0.1% SDS.

64 g steroidal methyl chenodeoxycholate, methyl deoxycholate, and 4-tert-butylcyclohexanol (cis/trans 1:

65 d in the presence of the bile salts cholate, deoxycholate, and chenodeoxycholate, and EMSA showed tha

66 etergents such as sodium dodecyl sulfate and deoxycholate, and it showed increased susceptibility to

67 ther anions - chloride, phosphate, pyruvate, deoxycholate, and lactate - also present in serum.

68 e extracted with a buffer containing Triton, deoxycholate, and SDS but not with a buffer containing T

69 tergents such as Triton X-100, Nonidet P-40, deoxycholate, and SDS tended to destabilize the CFTR dim

70 the anal verge were incubated in 1 mM sodium deoxycholate, and the percentage of goblet cells undergo

71 They are elicited by deoxycholate applied to either side of the membrane, wit

72 the intestinal microbiome-modified bile acid deoxycholate are increased in cirrhosis.

73 Micromolar concentrations of the bile salt deoxycholate are shown to rescue the activity of an inac

74 n of the addAB mutant restored resistance to deoxycholate, as well as function of the DNA double stra

75 ivated protein kinases did not attenuate the deoxycholate-associated increase in Mcl-1 protein, the R

76 with flucytosine (n = 94) or amphotericin B deoxycholate at 0.7-1.0 mg/kg/day with flucytosine (n =

77 ed upon addition of chlorpromazine or sodium deoxycholate at concentrations below the critical micell

78 Sodium deoxycholate at pH 9.0 solubilized about 35% of the rece

79 tive antifungal drugs such as amphotericin B deoxycholate (available for 52.5% of institutions), itra

80 e lies in the use of phospholipid and sodium deoxycholate-based nanoscale flexible lipoidal vesicles,

81 the amino acids proposed to be important for deoxycholate binding by IpaD appear to have significant

82 the wild-type enzyme reveals, as predicted, deoxycholate bound with its carboxyl group at the entran

83 ed from these marginal edges with a Tween-40/deoxycholate buffer that solubilizes the actin cytoskele

84 ommend initial treatment with amphotericin B deoxycholate, but this drug has substantial side effects

85 ere more sensitive than the parent strain to deoxycholate by varying degrees.

86 (serotonin, 2,4-dichlorophenoxyacetic acid, deoxycholate) can each partially substitute for the red

87 ents, e.g., Tween 20, sodium cholate, sodium deoxycholate, CHAPS, or CHAPSO, are completely ineffecti

88 cluding sodium dodecyl sulfate (SDS), sodium deoxycholate, Chaps, Triton X-100, Triton X-114, NP-40,

89 ected by the interaction with the bile salts deoxycholate, chenodeoxycholate, and taurodeoxcholate.

90 cid, palmitic acid, palmitoleic acid and the deoxycholate/cholate (DCA/CA) ratio, along with the dysr

91 lta ompU2 strain was deficient for growth in deoxycholate compared to wild-type, Delta ompT, and Delt

92 tment of seven daily doses of amphotericin B deoxycholate (control group) and was associated with few

93 AmB) compared to conventional amphotericin B deoxycholate (DAmB) is due to several factors including,

94 centration (MBC) of bile, the bile component deoxycholate (DC), and the anionic detergent sodium dode

95 r four bile acids, chenodeoxycholate (CDCA), deoxycholate (DCA), cholate (CA), and ursodeoxycholate (

96 Toward anionic Trition X-100/sodium deoxycholate/diC8PC (4:2:1) mixed micelles, L20W and L20

97 of the detergents sodium dodecyl sulfate and deoxycholate disrupted this interaction.

98 ric stoichiometry for the oligomer formed in deoxycholate (DOC) micelles, the high-resolution unproce

99 Exposure to the bile salt deoxycholate (DOC) significantly enhances Shigella virul

100 An exchange of the surfactant sodium deoxycholate (DOC) to specific single-stranded (ss)DNA s

101 appendages in response to bile salts such as deoxycholate (DOC), and that the formation of these appe

102 taining interactions are more abundant in 1% Deoxycholate (DOC), while Shank-, Homer- and mGluR5-cont

103 tolC mutant to grow in the presence of 0.05% deoxycholate (DOC).

104 escence and by insolubility in the detergent deoxycholate (DOC).

105 pylobacter may be triggered by the bile acid deoxycholate (DOC).

106 The bile salt sodium deoxycholate (DOC, 1-4 mM) caused a dose-dependent incre

107 In nerves exposed to the bile salt sodium deoxycholate (DOC, 6 min, 4 mM), challenge with elevated

108 ively; Phadebact, 100 and 98%, respectively; deoxycholate drop test, 99 and 98%, respectively; deoxyc

109 ic simulations revealed that the presence of deoxycholate enhances NaCl rejection in these graphene-b

110 ly inhibited by the detergents, Sarkosyl and deoxycholate, even at 0.025%, but it was not inhibited b

111 deoxycholate uptake and reduces tolerance to deoxycholate exposure.

112 off-patent antifungal drugs: amphotericin B deoxycholate, flucytosine, and fluconazole.

113 occal induction regimens: (1) amphotericin B deoxycholate for 4 weeks; (2) amphotericin and flucytosi

114 All three enzymes require sodium deoxycholate for optimal activities; other detergents ex

115 ompared voriconazole to amphotericin B (AmB) deoxycholate for the primary therapy of IA.

116 countries still often use the amphotericin B deoxycholate formulation because of a small number of ge

117 The conventional amphotericin B deoxycholate formulation has largely been replaced in hi

118 h AIDS, the preferred treatment has been the deoxycholate formulation of amphotericin B.

119 th cultures containing 0.05% (wt/vol) sodium deoxycholate, growth of the mutant was significantly inh

120 conferring full resistance to the bile salt deoxycholate, improving the efficiency of cell division

121 ling predicted that IpaD binds the bile salt deoxycholate in a cleft formed by the N-terminal domain

122 eriority criteria compared to amphotericin B deoxycholate in its registrational clinical trial.

123 the higher efficacy of voriconazole over AmB deoxycholate in mycologically documented IA.

124 t and independent attachment and invasion by deoxycholate in Shigella flexneri, deoxycholate negative

125 ce immunized with larval antigens soluble in deoxycholate in which protective immunity was shown to b

126 es the addition of a bile salt (e.g., sodium deoxycholate) in trace amounts to solutions of the phosp

127 Deoxycholate increased cellular Mcl-1 protein in a conce

128 Furthermore, deoxycholate increased NF-kappaB activity, associated wi

129 ow that submicellar concentrations of sodium deoxycholate induce time-resolved blocking events of Omp

130 Although deoxycholate induced apoptosis and activated all three c

131 Whereas the deoxycholate-induced increase in Mcl-1 reduced Fas-media

132 t negative construct for NF-kappaB prevented deoxycholate-induced p50 nuclear translocation and activ

133 decrease fibronectin incorporation into the deoxycholate insoluble matrix, and prevent fibronectin's

134 hich, over time, becomes incorporated in the deoxycholate-insoluble ECM in a similar fashion to FN.

135 corporation of FN(syn-) into fibrils and the deoxycholate-insoluble matrix could be stimulated by Mn2

136 and/or 70-kDa fragments to the cell surface, deoxycholate-insoluble matrix, and adsorbed 160-kDa cell

137 g individual roles of bile salts showed that deoxycholate is a robust biofilm inducer compared to cho

138 and chenodeoxycholate, and EMSA showed that deoxycholate is able to abolish the formation of BreR-P(

139 We propose that deoxycholate is able to interact with BreR and induce a

140 The voltage dependence remains even when deoxycholate is applied symmetrically, indicating that i

141 Amphotericin B deoxycholate is recommended against, because of substant

142 ons preferentially binds multiple conjugated deoxycholate ligands in a novel 3:1 binding mode essenti

143 its [CFU]/mL/day) differ from amphotericin B deoxycholate (mean EFA, 0.402 [95% CI, .360-.445] log10

144 The deoxycholate-mediated increase of cellular Mcl-1 protein

145 WNTs of varying length suspended with sodium deoxycholate (NaDOC) show unique dielectrophoretic prope

146 vasion by deoxycholate in Shigella flexneri, deoxycholate negatively regulates IcsA and MAM in S. son

147 d into approximately 70-kDa components after deoxycholate/Nonidet P-40 treatment.

148 to be less toxic than either amphotericin B deoxycholate or ABLC.

149 o a control arm or to receive amphotericin B deoxycholate or caspofungin treatment while undergoing s

150 We solubilized HisACAT-1 with the detergent deoxycholate or CHAPS (3-[(3-cholamidopropyl)-dimethylam

151 eveloped in eyes treated with amphotericin B deoxycholate or L-AmB (P < 0.05).

152 aB at the TTSA needle tip in the presence of deoxycholate or other bile salts.

153 amphotericin B compared with amphotericin B deoxycholate (OR 0.09, 95% CI 0.02-0.50, P=0.006) and su

154 of bile salts, e.g., sodium cholate, sodium deoxycholate, or CHAPS.

155 e containing 5 mmol/L each of the BS, sodium deoxycholate, PC, or Indo, alone and in combination, was

156 ommended regimen of 7 days of amphotericin B deoxycholate plus flucytosine for treatment of human imm

157 Deoxycholate prolongation of Mcl-1 turnover was blocked

158 We now show that deoxycholate promotes the stable recruitment of IpaB to

159 C. jejuni in physiological levels of sodium deoxycholate released all three CDT proteins, as well as

160 e dihydroxy bile acids chenodeoxycholate and deoxycholate resulted in an approximately 10-fold increa

161 h S. typhimurium and S. typhi in bile and in deoxycholate resulted in the induction or repression of

162 The interaction between AmB and sodium deoxycholate resulted in the oligomeric and poly-aggrega

163 ni on plates supplemented with the bile salt deoxycholate retarded the inhibitory effect of chloramph

164 Treatment of the organelles with Na2CO3 or deoxycholate reveal that calpain I, 78-kDa calpain II, a

165 instead, we utilize trypsin-friendly sodium deoxycholate (SDC) as an advantageous denaturant that ca

166 The bile salt sodium deoxycholate (SDC) enabled efficient extraction and disa

167 mployed decellularization detergents, sodium deoxycholate (SDC) or Triton X-100.

168 uids were obtained by doping lecithin/sodium deoxycholate (SDC) reverse micelles with a photochromic

169 ti bacA mutants are symbiotically defective, deoxycholate sensitive, and bleomycin resistant.

170 ion, cell surface hydrophobicity, and sodium deoxycholate sensitivity.

171 Cell surface-bound FBG is initially deoxycholate-soluble, which, over time, becomes incorpor

172 exposure of a number of enteric pathogens to deoxycholate stimulates a conserved survival response to

173 tively resistant to in vitro dissociation by deoxycholate, suggesting a change in cellular IkappaB co

174 With the detergent, deoxycholate, the endocytosis rate was restored to inter

175 icator (PRODAN), and a hydrophobic additive (deoxycholate) to detect terpenes.

176 Sodium deoxycholate treatment mimicked the effect of heat-kille

177 tivity nor its mRNA stability was altered by deoxycholate treatment.

178 cholate drop test, 99 and 98%, respectively; deoxycholate tube test, 100 and 99%, respectively; optoc

179 Surprisingly, cholate and deoxycholate, two of the most abundant and very closely

180 The latter was activated by treatment with deoxycholate under the same conditions as mammalian NF-k

181 encodes a periplasmic protein that promotes deoxycholate uptake and reduces tolerance to deoxycholat

182 bance in the test tube containing 10% sodium deoxycholate versus a blank control tube, after incubati

183 ot reduced by dithionite until the detergent deoxycholate was added to disrupt membranes.

184 ction of COX-2 mRNA by chenodeoxycholate and deoxycholate was due to increased transcription.

185 cifically, continuous growth of C. jejuni in deoxycholate was found to: 1) induce the production of r

186 Cellular sensitivity to the detergent deoxycholate was increased for each deletion mutant, imp

187 In turn, induction of Cdx2 expression by deoxycholate was mediated by binding sites in the proxim

188 y heating at 56 degrees C in the presence of deoxycholate were able to function as templates in an in

189 secondary BAs (such as conjugated cholate or deoxycholate) were significantly associated with improve

190 ance and 10-week mortality as amphotericin B deoxycholate when combined with flucytosine for the trea

191 ecting cell integrity; in contrast to sodium deoxycholate which enhanced insulin permeability but was

192 Deoxycholate, which interferes with the protein-protein

193 ed that the transporter binds to cholate and deoxycholate with micromolar affinity, and transport ass